“I was in a restaurant when I first heard about stem cell therapies.
And I’m a little bit shocked by what I heard,” said Dr. Richard H. Glick, director of the Division of Neurosciences at NYU Langone Medical Center.
“And I was so surprised to see how many different people that had been doing stem cell therapy, that were really excited and saying, ‘I’ve got this technology.’
I just think that’s exciting.
I think there’s so much potential for this.”
Glick is a pioneer in the field of stem cell technologies and a co-founder of Therapeutics, a company focused on developing stem cell therapeutics.
“What we’re seeing in stem cell research is a really good, healthy and very diverse group of people working on different things,” he said.
“There’s so many of us who are just working on these different things and that really helps me understand how to get these new technologies to the people who need them.”
The next step, according to Glick and others, is to translate those findings to human clinical trials.
And there are a number of exciting developments on the horizon.
In a new study published in the journal Nature Biotechnology, scientists from the University of Utah School of Medicine used a genetically modified version of a human cell to treat patients with a genetic disorder known as Duchenne muscular dystrophy.
The scientists developed the stem cell-based treatment by reprogramming a gene from the genetic material of a muscle cell called the interleukin-4 receptor.
The interleu-4 receptors are involved in the regulation of various immune responses.
The interleucin-3 receptor, which is expressed in the muscles of humans and dogs, also has been shown to be involved in various aspects of immune function.
“We found a pathway to this gene, called TNF-α, which causes interleukaemia in Duchennes,” said Hui Li, the lead author of the study.
“When we reprogrammed this TNFα-specific gene, we found that it caused interleukemic disease.
And then we did the same thing with the TNF receptor-specific genes.
We found that these TNF receptors are associated with Duchenniem muscular dystrophies.
It’s a really interesting discovery.”
The researchers used the engineered cells to treat a patient with Duchesne muscular Dystrophy, and the resulting treatment showed significant improvement in the disease severity and overall health.
The study was a collaboration between researchers at the University at Buffalo and the University Health Network.
“In our clinical trials, we have shown that in a subset of Duchennes patients, we can significantly reduce the number of interleukes with interleutin-6 and interleuvin-5,” said Jennifer P. Shaffer, Ph.
D., a professor in the Department of Neurobiology and Systems Biology at the UB School of Engineering and Applied Science.
“So the goal was to show that these are drugs that could help patients with Duchene muscular dystroke.”
To test the efficacy of the therapy, the researchers transplanted the cells into patients with other Duchennie muscular dysteics, and compared their symptoms and health with those of those patients who received the cells from a control group.
“When we were able to transplant these cells into these patients, they showed improved symptoms and better health than they had before,” Shaffer said.
The researchers plan to conduct additional clinical trials of the treatment.
To learn more about the technology and its potential applications, visit the University and the UH Network website at www.usnbc.com.
For more on the Duchennis patients, visit www.duchennis.org.